SEARCH

SEARCH BY CITATION

REFERENCES

  • Berger, C.C., Bokemeyer, C., Schuppert, F. and Schmoll, H.J., Endocrinological late effects after chemotherapy for testicular cancer. Brit. J. Cancer, 73, 1108-1114 (1996). Medline
  • Bissett, D., Kunkeler, L., Zwanenburg, L., Paul, J., Gray, C., Swan, I.R., Kerr, D.J. and Kaye, S.B., Long-term sequelae of treatment for testicular germ cell tumours. Brit. J. Cancer, 62, 655-659 (1990). Medline
  • Bokemeyer, C., Berger, C.C., Hartmann, J.T., Kollmannsberger, C., Schmoll, H.J., Kuczyk, M.A. and Kanz, L., Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Brit. J. Cancer, 77, 1355-1362 (1998). Medline
  • Bokemeyer, C., Berger, C.C., Kuczyk, M.A. and Schmoll, H.J., Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. clin. Oncol., 14, 2923-2932 (1996). Medline
  • Bokemeyer, C., Hartmann, J.T., Fels, L., Knop, S., Brugger, W., Stolte, H. and Anz, L., Amifostine protects against early cisplatin-induced renal damage and enhances CD34+-cell numbers for PBSC-collection. Proc. Amer. Soc. clin. Oncol., 16, 47a (1997). Abstract nr. 166.
  • Bokemeyer, C. and 15 others, A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Europ. J. Cancer, 29A, 2225-2231 (1993).
  • Coleman, M.P., Esteve, J., Damiecki, P., Arslan, A. and Renard, H., Trends in cancer incidence and mortality, IARC Scientific Publication, IARC, Lyon, France, 12, 1-806 (1993).
  • Daugaard, G., Rossing, N. and Rorth, M., Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol., 21, 163-167 (1988). Medline
  • Dunn, T.A., Schmoll, H.J., Grunwald, V., Bokemeyer, C. and Casper, J., Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs, 7, 795-799 (1996). Medline
  • Fjeldborg, P., Sorensen, J. and Helkjaer, P.E., The long-term effect of cisplatin on renal function. Cancer, 58, 2214-2217 (1986). Medline
  • Groth, S., Nielsen, H., Sorensen, J.B., Christensen, A.B., Pedersen, A.G. and Rorth, M., Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother. Pharmacol., 17, 191-196 (1986). Medline
  • Hamilton, C.R., Bliss, J.M. and Horwich, A., The late effects of cis-platinum on renal function. Europ. J. Cancer clin. Oncol., 25, 185-189 (1989). Medline
  • Hansen, S.W., Groth, S., Daugaard, G., Rossing, N. and Rorth, M., Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J. clin. Oncol., 6, 1728-1731 (1988). Medline
  • Hansen, S.W., Helweg Larsen, S. and Trojaborg, W., Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J. clin. Oncol., 7, 1457-1461 (1989). Medline
  • Hansen, S.W. and Olsen, N., Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold. J. clin. Oncol., 7, 940-942 (1989). Medline
  • Hartmann, J.T., Albrecht, C., Schmoll, H.J., Kollmannsberger, C. and Bokemeyer, C., Long-term effects on sexual functioning and fertility after treatment for testicular cancer. Brit. J. Cancer, 80, 801-807 (1999a). Medline
  • Hartmann, J.T., Kanz, L. and Bokemeyer, C., Diagnosis and treatment of patients with testicular cancer. Drugs, 58, 257-281 (1999b). Medline
  • Hartmann, J.T., von Wangerow, A., Knop, S., Fels, L., Brugger, W., Stolte, H., Kanz, L. and Bokemeyer, C., A randomized trial comparing the toxicity of high dose chemotherapy with carboplatin, etoposide and ifosfamide plus PBSC transplantation (HD-VIC) with or without amifostine in patients with solid tumors. Proc. Amer. Soc. clin. Oncol., 18, 587a (1999c). Abstract nr. 2266.
  • Hernes, E.H., Harstad, K. and Fosså, S.D., Changing incidence and delay of testicular cancer in southern Norway (1981-1992). Europ. Urol., 30, 349-357 (1996).
  • Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D. and Glick, J., Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J. clin. Oncol., 14, 2101-2112 (1996). Medline
  • Macleod, P.M., Tyrell, C.J. and Keeling, D.H., The effect of cisplatin on renal function in patients with testicular tumours. Clin. Radiol., 39, 190-192 (1988). Medline
  • Moul, J.W., Robertson, J.E., George, S.L., Paulson, D.F. and Walther, P.J., Complications of therapy for testicular cancer. J. Urol., 142, 1491-1496 (1989). Medline
  • Nichols, C.R., Testicular cancer. Curr. Probl. Cancer, 22, 187-274 (1998). Medline
  • Osanto, S., Bukman, A., van Hoek, F., Sterk, P.J., de Llaat, J.A. and Hermans, J., Long-term effects of chemotherapy in patients with testicular cancer. J. clin. Oncol., 10, 574-579 (1992). Medline
  • Reddel, R.R., Kefford, R.F., Grant, J.M., Coates, A.S., Fox, R.M. and Tattersall, M.H., Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat. Rep., 66, 19-23 (1982). Medline
  • Roth, B.J., Einhorn, L.H. and Greist, A., Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin. Oncol., 15, 345-350 (1988). Medline
  • Schuchter, L.M., Meropol, N. and Glick, J.H., Radiation and chemotherapy protectors. In: V.T.De Vita, S.Hellmann and S.A.Rosenberg (eds.), Cancer principles and practice of oncology (5th ed.), pp. 387-392, Lippincott-Raven, Philadelphia (1997).
  • Siegert, W., Beyer, J., Strohscheer, I., Baurmann, H., Oettle, H., Zingsem, J., Zimmermann, R., Bokemeyer, C., Schmoll, H.J. and Hühn, D., High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J. clin. Oncol., 12, 1223-1231 (1994). Medline
  • Teutsch, C., Lipton, A. and Harvey, H.A., Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat. Rep., 61, 925-926 (1977). Medline
  • Thompson, S.W., Davis, L.E., Kornfeld, M., Hilgers, R.D. and Standefer, J.C., Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer, 54, 1269-1275 (1984). Medline
  • Treskes, M. and van der Vijgh, W.J., WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach. Cancer Chemother. Pharmacol., 33, 93-106 (1993). Medline
  • van der Hulst, R.J., Dreschler, W.A. and Urbanus, N.A., High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann. Otol. Rhinol. Laryngol., 97, 133-137 (1988). Medline
  • Vogelzang, N.J., Bosl, G.J., Johnson, K. and Kennedy, B.J., Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann. Intern. Med., 95, 288-292 (1981). Medline
  • Wagstaff, A.J., Ward, A., Benfield, P. and Heel, R.C., Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37, 162-190 (1989). Medline
  • Yagoda, A., Mukherji, B., Young, C., Etcubanas, E., Lamonte, C., Smith, J.R., Tan, C.T. and Krakoff, I.H., Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann. Intern. Med., 77, 861-870 (1972). Medline